Aeon Global Health (OTCMKTS: AGHC) is one of 23 public companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare Aeon Global Health to similar companies based on the strength of its institutional ownership, dividends, risk, profitability, analyst recommendations, earnings and valuation.
This table compares Aeon Global Health and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aeon Global Health||-50.13%||-236.70%||-63.13%|
|Aeon Global Health Competitors||-97.44%||-120.85%||-36.20%|
Earnings & Valuation
This table compares Aeon Global Health and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aeon Global Health||$16.30 million||-$8.00 million||-0.71|
|Aeon Global Health Competitors||$1.13 billion||$90.54 million||511.17|
Aeon Global Health’s rivals have higher revenue and earnings than Aeon Global Health. Aeon Global Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings for Aeon Global Health and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aeon Global Health||0||0||1||0||3.00|
|Aeon Global Health Competitors||131||552||658||36||2.44|
As a group, “Medical laboratories” companies have a potential downside of 2.79%. Given Aeon Global Health’s rivals higher probable upside, analysts clearly believe Aeon Global Health has less favorable growth aspects than its rivals.
Risk & Volatility
Aeon Global Health has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Aeon Global Health’s rivals have a beta of 1.37, suggesting that their average stock price is 37% more volatile than the S&P 500.
Institutional and Insider Ownership
51.5% of shares of all “Medical laboratories” companies are held by institutional investors. 11.5% of Aeon Global Health shares are held by company insiders. Comparatively, 17.4% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Aeon Global Health rivals beat Aeon Global Health on 9 of the 12 factors compared.
About Aeon Global Health
AEON Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through two segments, Laboratory Testing Services and Web-Based Software. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, and compliance with regulatory requirements. In addition, AEON Global Health Corp. offers post contract customer support services. The company was formerly known as Authentidate Holding Corp. and changed its name to AEON Global Health Corp. in January 2018. AEON Global Health Corp. is based in Gainesville, Georgia.
Receive News & Ratings for Aeon Global Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeon Global Health and related companies with MarketBeat.com's FREE daily email newsletter.